[8-K] Moleculin Biotech, Inc. Reports Material Event
Item 7.01 鈥� Regulation FD: On 30 Jul 2025 Moleculin Biotech, Inc. (NASDAQ: MBRX) furnished an 8-K announcing it has received a Notice of Intent to Grant for European patent application 鈥淧reparation of Pre-liposomal Annamycin Lyophilizate.鈥�
The disclosure, provided via attached Exhibit 99.1, indicates the patent is expected to cover the Company鈥檚 Annamycin formulation in Europe once formally issued. No financial statements, earnings data or other operational metrics are included. The information is expressly furnished, not filed, and therefore will not be incorporated into other Exchange Act or Securities Act reports unless later referenced. Exhibit 104 supplies the Inline XBRL cover page.
Voce 7.01 鈥� Regolamento FD: Il 30 luglio 2025 Moleculin Biotech, Inc. (NASDAQ: MBRX) ha presentato un modulo 8-K comunicando di aver ricevuto un Avviso di Intenzione di Concessione per la domanda di brevetto europea 鈥淧reparazione del Liofilizzato Pre-liposomiale di Annamicina.鈥�
La comunicazione, fornita tramite l'Esibizione 99.1 allegata, indica che il brevetto dovrebbe coprire la formulazione di Annamicina della Societ脿 in Europa una volta formalmente rilasciato. Non sono inclusi bilanci finanziari, dati sugli utili o altri indicatori operativi. Le informazioni sono espressamente fornite, non depositate, e pertanto non saranno incorporate in altri rapporti ai sensi del Exchange Act o del Securities Act a meno che non vengano successivamente richiamate. L'Esibizione 104 contiene la pagina di copertura Inline XBRL.
Art铆culo 7.01 鈥� Reglamento FD: El 30 de julio de 2025, Moleculin Biotech, Inc. (NASDAQ: MBRX) present贸 un formulario 8-K anunciando que ha recibido un Aviso de Intenci贸n de Concesi贸n para la solicitud de patente europea 鈥淧reparaci贸n del Liofilizado Pre-liposomal de Annamicina.鈥�
La divulgaci贸n, proporcionada a trav茅s del Anexo 99.1 adjunto, indica que se espera que la patente cubra la formulaci贸n de Annamicina de la Compa帽铆a en Europa una vez emitida formalmente. No se incluyen estados financieros, datos de ganancias ni otras m茅tricas operativas. La informaci贸n se proporciona expresamente como suministrada, no presentada, y por lo tanto no se incorporar谩 en otros informes bajo la Exchange Act o Securities Act a menos que se haga referencia posteriormente. El Anexo 104 proporciona la portada Inline XBRL.
頃 7.01 鈥� 攴滌爼 FD: 2025雲� 7鞗� 30鞚�, Moleculin Biotech, Inc. (NASDAQ: MBRX)鞚� 鞙犽熃 韸鬼棃 於滌洂 鈥滍攧毽�-毽彫膦� 鞎堧倶毵堨澊鞁� 霃欔舶瓯挫“鞝滌潣 鞝滌“鈥濎棎 雽�頃� 項堦皜 鞚橃偓 韱奠靹�毳� 氚涭晿鞚岇潉 鞎岆Μ電� 8-K毳� 鞝滌稖頄堨姷雼堧嫟.
觳秬霅� Exhibit 99.1鞚� 韱淀暣 鞝滉车霅� 瓿奠嫓電� 頃措嫻 韸鬼棃臧� 鞝曥嫕鞙茧 氚滉笁霅橂┐ 須岇偓鞚� 鞎堧倶毵堨澊鞁� 鞝滍槙鞚� 鞙犽熃鞐愳劀 氤错樃頃� 瓴冹溂搿� 鞓堨儊霅滊嫟瓿� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟. 鞛鞝滍憸, 靾橃澋 雿办澊韯� 霕愲姅 旮绊儉 鞖挫榿 歆�響滊姅 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟. 鞚� 鞝曤炒電� 氇呾嫓鞝侅溂搿� 鞝滌稖霅� 瓴冹澊 鞎勲媽 鞝滉车霅� 瓴�鞚措┌, 鞚错泟 彀胳“霅橃 鞎婋姅 頃� 雼るジ Exchange Act 霕愲姅 Securities Act 氤搓碃靹滌棎 韱淀暕霅橃 鞎婌姷雼堧嫟. Exhibit 104電� Inline XBRL 響滌 韼橃澊歆�毳� 鞝滉车頃╇媹雼�.
Point 7.01 鈥� R猫glement FD : Le 30 juillet 2025, Moleculin Biotech, Inc. (NASDAQ : MBRX) a soumis un formulaire 8-K annon莽ant qu'elle a re莽u un Avis d'Intention d'Octroi pour la demande de brevet europ茅enne 芦 Pr茅paration du lyophilisat pr茅-liposomal d'Annamycine 禄.
La divulgation, fournie via l'Exhibit 99.1 joint, indique que le brevet devrait couvrir la formulation d'Annamycine de la Soci茅t茅 en Europe une fois officiellement d茅livr茅. Aucun 茅tat financier, donn茅es sur les r茅sultats ou autres indicateurs op茅rationnels ne sont inclus. Les informations sont express茅ment fournies, non d茅pos茅es, et ne seront donc pas int茅gr茅es dans d'autres rapports au titre de l'Exchange Act ou du Securities Act sauf s'ils sont ult茅rieurement r茅f茅renc茅s. L'Exhibit 104 fournit la page de couverture Inline XBRL.
Posten 7.01 鈥� Regulation FD: Am 30. Juli 2025 reichte Moleculin Biotech, Inc. (NASDAQ: MBRX) ein 8-K ein und gab bekannt, dass es eine Absichtserkl盲rung zur Erteilung f眉r die europ盲ische Patentanmeldung 鈥濰erstellung des pr盲-liposomalen Annamycin-Lyophilisats鈥� erhalten hat.
Die Offenlegung, bereitgestellt durch die angeh盲ngte Anlage 99.1, weist darauf hin, dass das Patent voraussichtlich die Annamycin-Formulierung des Unternehmens in Europa abdecken wird, sobald es formell erteilt wird. Es sind keine Finanzberichte, Gewinnzahlen oder andere operative Kennzahlen enthalten. Die Informationen werden ausdr眉cklich bereitgestellt, nicht eingereicht und werden daher nicht in andere Berichte nach dem Exchange Act oder Securities Act aufgenommen, es sei denn, sie werden sp盲ter referenziert. Anlage 104 enth盲lt die Inline-XBRL-Titelseite.
- Received Notice of Intent to Grant for European patent covering Pre-liposomal Annamycin Lyophilizate, enhancing prospective IP protection in a key market.
- None.
Insights
TL;DR: European patent notice modestly improves MBRX competitive moat; financial impact not yet quantifiable.
The notice of intent to grant extends future intellectual-property protection for Annamycin, Moleculin鈥檚 lead oncology candidate. Stronger IP in a major market can enhance pricing power and partnering leverage, supporting long-term value. However, with no accompanying clinical or revenue data, the immediate valuation effect is limited. Given Moleculin鈥檚 development-stage status, any IP progress is material but preliminary.
TL;DR: Pending EU patent reduces regulatory risk for Annamycin formulation, a clear strategic positive.
An EU 鈥渘otice of intent鈥� typically precedes formal patent issuance within months, locking in 20-year protection from the filing date. This strengthens Moleculin鈥檚 bargaining position for regional licensing or funding. The filing lacks details on claims scope, but simply advancing to grant stage is a de-risking milestone for a small-cap biotech.
Voce 7.01 鈥� Regolamento FD: Il 30 luglio 2025 Moleculin Biotech, Inc. (NASDAQ: MBRX) ha presentato un modulo 8-K comunicando di aver ricevuto un Avviso di Intenzione di Concessione per la domanda di brevetto europea 鈥淧reparazione del Liofilizzato Pre-liposomiale di Annamicina.鈥�
La comunicazione, fornita tramite l'Esibizione 99.1 allegata, indica che il brevetto dovrebbe coprire la formulazione di Annamicina della Societ脿 in Europa una volta formalmente rilasciato. Non sono inclusi bilanci finanziari, dati sugli utili o altri indicatori operativi. Le informazioni sono espressamente fornite, non depositate, e pertanto non saranno incorporate in altri rapporti ai sensi del Exchange Act o del Securities Act a meno che non vengano successivamente richiamate. L'Esibizione 104 contiene la pagina di copertura Inline XBRL.
Art铆culo 7.01 鈥� Reglamento FD: El 30 de julio de 2025, Moleculin Biotech, Inc. (NASDAQ: MBRX) present贸 un formulario 8-K anunciando que ha recibido un Aviso de Intenci贸n de Concesi贸n para la solicitud de patente europea 鈥淧reparaci贸n del Liofilizado Pre-liposomal de Annamicina.鈥�
La divulgaci贸n, proporcionada a trav茅s del Anexo 99.1 adjunto, indica que se espera que la patente cubra la formulaci贸n de Annamicina de la Compa帽铆a en Europa una vez emitida formalmente. No se incluyen estados financieros, datos de ganancias ni otras m茅tricas operativas. La informaci贸n se proporciona expresamente como suministrada, no presentada, y por lo tanto no se incorporar谩 en otros informes bajo la Exchange Act o Securities Act a menos que se haga referencia posteriormente. El Anexo 104 proporciona la portada Inline XBRL.
頃 7.01 鈥� 攴滌爼 FD: 2025雲� 7鞗� 30鞚�, Moleculin Biotech, Inc. (NASDAQ: MBRX)鞚� 鞙犽熃 韸鬼棃 於滌洂 鈥滍攧毽�-毽彫膦� 鞎堧倶毵堨澊鞁� 霃欔舶瓯挫“鞝滌潣 鞝滌“鈥濎棎 雽�頃� 項堦皜 鞚橃偓 韱奠靹�毳� 氚涭晿鞚岇潉 鞎岆Μ電� 8-K毳� 鞝滌稖頄堨姷雼堧嫟.
觳秬霅� Exhibit 99.1鞚� 韱淀暣 鞝滉车霅� 瓿奠嫓電� 頃措嫻 韸鬼棃臧� 鞝曥嫕鞙茧 氚滉笁霅橂┐ 須岇偓鞚� 鞎堧倶毵堨澊鞁� 鞝滍槙鞚� 鞙犽熃鞐愳劀 氤错樃頃� 瓴冹溂搿� 鞓堨儊霅滊嫟瓿� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟. 鞛鞝滍憸, 靾橃澋 雿办澊韯� 霕愲姅 旮绊儉 鞖挫榿 歆�響滊姅 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟. 鞚� 鞝曤炒電� 氇呾嫓鞝侅溂搿� 鞝滌稖霅� 瓴冹澊 鞎勲媽 鞝滉车霅� 瓴�鞚措┌, 鞚错泟 彀胳“霅橃 鞎婋姅 頃� 雼るジ Exchange Act 霕愲姅 Securities Act 氤搓碃靹滌棎 韱淀暕霅橃 鞎婌姷雼堧嫟. Exhibit 104電� Inline XBRL 響滌 韼橃澊歆�毳� 鞝滉车頃╇媹雼�.
Point 7.01 鈥� R猫glement FD : Le 30 juillet 2025, Moleculin Biotech, Inc. (NASDAQ : MBRX) a soumis un formulaire 8-K annon莽ant qu'elle a re莽u un Avis d'Intention d'Octroi pour la demande de brevet europ茅enne 芦 Pr茅paration du lyophilisat pr茅-liposomal d'Annamycine 禄.
La divulgation, fournie via l'Exhibit 99.1 joint, indique que le brevet devrait couvrir la formulation d'Annamycine de la Soci茅t茅 en Europe une fois officiellement d茅livr茅. Aucun 茅tat financier, donn茅es sur les r茅sultats ou autres indicateurs op茅rationnels ne sont inclus. Les informations sont express茅ment fournies, non d茅pos茅es, et ne seront donc pas int茅gr茅es dans d'autres rapports au titre de l'Exchange Act ou du Securities Act sauf s'ils sont ult茅rieurement r茅f茅renc茅s. L'Exhibit 104 fournit la page de couverture Inline XBRL.
Posten 7.01 鈥� Regulation FD: Am 30. Juli 2025 reichte Moleculin Biotech, Inc. (NASDAQ: MBRX) ein 8-K ein und gab bekannt, dass es eine Absichtserkl盲rung zur Erteilung f眉r die europ盲ische Patentanmeldung 鈥濰erstellung des pr盲-liposomalen Annamycin-Lyophilisats鈥� erhalten hat.
Die Offenlegung, bereitgestellt durch die angeh盲ngte Anlage 99.1, weist darauf hin, dass das Patent voraussichtlich die Annamycin-Formulierung des Unternehmens in Europa abdecken wird, sobald es formell erteilt wird. Es sind keine Finanzberichte, Gewinnzahlen oder andere operative Kennzahlen enthalten. Die Informationen werden ausdr眉cklich bereitgestellt, nicht eingereicht und werden daher nicht in andere Berichte nach dem Exchange Act oder Securities Act aufgenommen, es sei denn, sie werden sp盲ter referenziert. Anlage 104 enth盲lt die Inline-XBRL-Titelseite.
|
|
|
|
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification
No.)
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
|
|
Title of each class
|
Trading Symbol (s)
|
Name of each exchange on which registered
|
|
|
|
The
|
|
Item 7.01
|
Regulation FD Disclosure
|
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
Exhibit
No.
|
Description
|
|
99.1
|
Press Releasedated July 30, 2025
|
|
104
|
Cover page Interactive Data File (formatted as Inline XBRL document)
|
|
MOLECULIN BIOTECH, INC.
|
|||
|
Date:
|
July 30, 2025
|
||
|
By:
|
/s/ Jonathan P. Foster
|
||
|
Jonathan P. Foster
|
|||
Source:
FAQ
What did Moleculin Biotech (MBRX) disclose in its 30 July 2025 Form 8-K?
Which item of Form 8-K does the disclosure fall under?
Does the filing include financial statements or earnings data?
Where can investors read the full press release?
Is the disclosed information considered filed or furnished?
